HeartBeam Launches Pilot Study for On-Demand 12-Lead ECG Patch to Detect Ischemia

HeartBeam Inc. (NASDAQ: BEAT) has announced the launch of a pilot study to evaluate its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia. The study marks a significant step in the development of the HeartBeam patch, which the company believes has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry markets.

Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to address a critical gap in ambulatory monitoring.

“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could provide physicians with actionable data to detect ischemia in a outpatient setting.”

The pilot study will test the patch's ability to capture high-quality ECG signals on demand, which could enable earlier detection of reduced blood flow to the heart muscle. Current patch monitors typically record single-lead or limited-lead ECGs continuously, but they lack the capability to produce the comprehensive 12-lead view that is standard for diagnosing ischemia in clinical settings.

If successful, the HeartBeam patch could offer a non-invasive, convenient alternative for patients who need prolonged monitoring without the inconvenience of traditional Holter monitors or event recorders. The company aims to provide clinical-grade insights over extended periods, potentially reducing the need for in-hospital testing and enabling remote patient management.

The study's launch comes as the prevalence of coronary artery disease intensifies with aging populations and increasing cardiovascular risk factors. HeartBeam's approach could help bridge the gap between intermittent in-clinic ECGs and continuous monitoring, offering on-demand diagnostic capability when symptoms occur.

For more information on HeartBeam, visit the company's newsroom at https://nnw.fm/BEAT.

NetworkNewsWire (NNW) is a specialized communications platform focusing on financial news and content distribution. For more details, see the full terms of use and disclaimers at https://www.NetworkNewsWire.com/Disclaimer.